title: Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems.
abstract: Passive immunotherapy using anti-HIV broadly neutralizing monoclonal antibodies (mAbs) has shown promise as an HIV treatment, reducing mother-to-child-transmission (MTCT) of simian/human immunodeficiency virus (SHIV) in non-human primates and decreasing viral rebound in patients who ceased receiving anti-viral drugs. In addition, a cocktail of potent mAbs may be useful as mucosal microbicides and provide an effective therapy for post-exposure prophylaxis. However, even highly neutralizing HIV mAbs used today may lose their effectiveness if resistance occurs, requiring the rapid production of new or engineered mAbs on an ongoing basis in order to counteract the viral resistance or the spread of a certain HIV-1 clade in a particular region or patient. Plant-based expression systems are fast, inexpensive and scalable and are becoming increasingly popular for the production of proteins and monoclonal antibodies. In the present study, Agrobacterium-mediated transient transfection of plants, utilizing two species of Nicotiana, have been tested to rapidly produce high levels of an HIV 89.6PΔ140env and several well-studied anti-HIV neutralizing monoclonal antibodies (b12, 2G12, 2F5, 4E10, m43, VRC01) or a single chain antibody construct (m9), for evaluation in cell-based viral inhibition assays. The protein-A purified plant-derived antibodies were intact, efficiently bound HIV envelope, and were equivalent to, or in one case better than, their counterparts produced in mammalian CHO or HEK-293 cells in both neutralization and antibody dependent viral inhibition assays. These data indicate that transient plant-based transient expression systems are very adaptable and could rapidly generate high levels of newly identified functional recombinant HIV neutralizing antibodies when required. In addition, they warrant detailed cost-benefit analysis of prolonged incubation in plants to further increase mAb production.
authors.affiliation: PlantVax Corporation, Rockville, Maryland, United States of America. yjr@plantvax.com
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Rosenberg
authors.forename: Markus
authors.initials: M
authors.lastname: Sack
authors.forename: David
authors.initials: D
authors.lastname: Montefiori
authors.forename: Donald
authors.initials: D
authors.lastname: Forthal
authors.forename: Lingjun
authors.initials: L
authors.lastname: Mao
authors.forename: Segundo
authors.initials: S
authors.lastname: Hernandez-Abanto
authors.forename: Lori
authors.initials: L
authors.lastname: Urban
authors.forename: Gary
authors.initials: G
authors.lastname: Landucci
authors.forename: Rainer
authors.initials: R
authors.lastname: Fischer
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Jiang
mesh_terms: D060054:Agrobacterium / Q000235:genetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics; D057134:Antibodies, Neutralizing / Q000096:biosynthesis* / Q000235:genetics; D016466:CHO Cells; D006224:Cricetinae; D004797:Enzyme-Linked Immunosorbent Assay; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D030821:Plants, Genetically Modified / Q000235:genetics / Q000378:metabolism; D020349:Surface Plasmon Resonance; D014026:Nicotiana / Q000235:genetics / Q000378:metabolism; D014162:Transfection
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies